News & analysis, rated.
Breaking AI developments, in-depth guides, real-world case studies, and analysis — each one rated so you know what matters.
Four biotech IPOs topped $400M in 2026, highest pace since 2021
Kardigan's heart drug unit raised $400M this week, joining three peers in a biotech IPO rebound. Here's what the capital surge signals about investor appetite.
Surgeon's microsurgery robot gives steadier hands than human control
MMI built a robot to help surgeons perform microsurgical procedures with greater precision than the human hand alone allows. Here's what the system does and who benefits.
Medtech M&A surges past 2025 record with Boston Scientific, Danaher deals
Medtech deal volumes and values are outpacing the first half of 2025, driven by major acquisitions including Boston Scientific's Penumbra buyout and Danaher's Masimo acquisition. Here's what the trend signals for the sector.
FDA warns breast biopsy needle shortage extends to 2027
The FDA says shortages of certain breast biopsy needles will persist through 2027, following Hologic's January market removal. What hospitals should expect.
Distalmotion expands Dexter robotic surgery to more gynecology procedures
Swiss robotics firm Distalmotion is adding new surgical indications for its Dexter system in the U.S. market, targeting ambulatory surgery centers seeking higher utilization rates.
Lifepoint promotes CFO Aaron Lewis to COO as health system expands
Aaron Lewis moves from CFO to chief operating officer at Lifepoint Health, signaling the system's focus on geographic expansion and service diversification.
ACA marketplace insurers drop to 9 per state as policy shifts scare carriers
Average insurer participation fell from 9.6 to 9 states in 2026, per KFF. Policy turmoil is driving carriers away from ACA exchanges—what this means for your coverage options.
CBO questions No Surprises Act impact on healthcare prices
The Congressional Budget Office says the 2020 No Surprises Act may not be controlling costs as expected. The agency is asking for fresh research into what the law actually changed.
In silico trials cut drug costs 60%, shorten timelines 40%
AI-driven simulation could slash clinical trial expenses and accelerate approvals. A new analysis quantifies the economics—and reveals what pharma needs to move faster.
Job offer acceptance drops to 48% as candidate leverage shifts
Gartner data shows job offer acceptance fell from 85% two years ago to 48% in Q4 2025. What candidates are demanding instead.
Gartner maps essential AI governance platform features
Gartner identifies the critical capabilities enterprises need in AI governance platforms. Learn what separates functional tools from compliance theater.
Gartner rates OpenText's 2026 strengths and gaps
Gartner publishes its annual assessment of OpenText's competitive position, listing specific capabilities buyers prefer and areas the vendor needs to address.